The personalized cancer vaccine field had its first true clinical success with the KEYNOTE-942 study, where patients with resected melanoma were treated with Merck’s PD-1 inhibitor pembrolizumab (Keytruda) with or without Moderna’s mRNA/LNP personalized vaccine product (mRNA-4157).